Titre :
  • Everolimus plus exemestane as first-line therapy in HR+, HER2- advanced breast cancer in BOLERO-2
Auteur : Beck, Joseph Thaddeus ; Hortobagyi, Gabriel N. ; Campone, Mario ; Lebrun, Fabienne ; Piccart-Gebhart, Martine ; Deleu, Ines I. ; Rugo, Hope ; Pistilli, Barbara B. ; Masuda, Norikazu ; Hart, Lowell L.L. ; Melichar, Bohuslav B. ; Dakhil, Shaker S. ; Geberth, Matthias M. ; Nunzi, Martina M. ; Heng, Daniel Y C D.Y.C. ; Brechenmacher, Thomas T. ; El-Hashimy, Mona M. ; Douma, Shyanne S. ; Ringeisen, François F.
Informations sur la publication : Breast cancer research and treatment, 143, 3, (page 459-467)
Statut de publication : Publié, 2014-02
Sujet CREF : Cancérologie
Mots-clés : BOLERO-2
Breast cancer
Everolimus
First-line therapy
Metastatic disease
mTOR inhibition
Mots-clés MeSH : Aged
Aged, 80 and over
Androstadienes -- administration & dosage
Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
Breast Neoplasms -- drug therapy -- genetics -- pathology
Clinical Trials as Topic
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Middle Aged
Neoplasm Recurrence, Local -- drug therapy -- pathology
Neoplasms, Hormone-Dependent -- drug therapy -- genetics -- pathology
Receptors, Estrogen -- genetics
Receptors, Progesterone -- genetics
Sirolimus -- administration & dosage -- analogs & derivatives
Note : SCOPUS: ar.j
Langue :
  • Anglais
Identificateurs : urn:issn:0167-6806 
info:doi/10.1007/s10549-013-2814-5
info:pmid/24362951